Related Experiment Video
Updated: Oct 30, 2025
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Reduction in and Preventive Effects for Oral-Cancer Risk with Antidepressant Treatment
Chia-Min Chung1,2,3, Tzer-Min Kuo3, Kun-Tu Yeh4
1Center for Drug Abuse and Addiction, China Medical University Hospital, Taichung 40447, Taiwan.
Abstract:
Areca nut (AN) was identified as carcinogenic to humans. Around 600 million people globally use AN in some form, yet no effective therapeutic drug is available to overcome AN addiction. This preclinical study examines the effects of antidepressants on AN use with animal models. We produced AN powder and dissolved it into drinking water, training 55 C57BL/6 mice in free self-selection to drink AN water or normal water. Then, the mice were randomly divided into four groups. Selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs) were given as three treatment groups and one placebo group for four weeks. In the follow-up period, the preference and amount of free selection of AN and normal water, and oral pathological change were evaluated. There was a significant decrease in preference for AN drinking during the first four weeks, and the 36th week after drug withdrawal in the MAOI and SSRI groups (all p < 0.05). The drug-reducing effect of AN water in the 1-4-week period was significant in the MAOI group (p < 0.0001) and was also significant in the 3-4-week period in the SSRI group (p = 0.03). The TCA group did not show a decrease effect. At the endpoint (60 weeks), oral mucosal fibrosis (OSF) levels and risk in the SSRI (p = 0.0081) and MAOI (p = 0.01) groups were significantly lower than those in the control group. Antidepressant drugs MAOIs and SSRIs could reduce the amount of AN use and decrease the early stage of oral fibrosis in mice, but SSRIs may need to be boosted again.
Insights
Antidepressants like MAOIs and SSRIs reduced areca nut (AN) consumption and early oral fibrosis in mice. Tricyclic antidepressants showed no effect, and SSRIs may require further boosting.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Areca nut (AN) use is a global health concern, linked to carcinogenicity, with no effective treatments for addiction.
- Millions worldwide consume AN, highlighting the urgent need for therapeutic interventions.
- Preclinical research is crucial to explore potential treatments for AN addiction and its associated oral pathologies.
Purpose of the Study:
- To investigate the efficacy of different classes of antidepressants in reducing AN consumption in an animal model.
- To evaluate the impact of antidepressants on the development of oral pathological changes, specifically oral submucous fibrosis (OSF).
- To compare the effects of Monoamine Oxidase Inhibitors (MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Tricyclic Antidepressants (TCAs) against a placebo.
Main Methods:
- Established an animal model using C57BL/6 mice trained to self-select between AN-laced water and normal water.
- Administered MAOIs, SSRIs, and TCAs to separate treatment groups, with one group receiving a placebo, over a four-week period.
- Monitored AN and water intake, preference, and assessed oral pathological changes, including OSF, over a 60-week endpoint.
Main Results:
- MAOIs and SSRIs significantly decreased AN preference and consumption during and after the treatment period (p < 0.05).
- MAOIs demonstrated a strong drug-reducing effect on AN water intake (p < 0.0001), while SSRIs showed a significant effect in later weeks (p = 0.03).
- Both MAOI and SSRI treatments significantly reduced oral mucosal fibrosis (OSF) risk at 60 weeks (p < 0.01), unlike TCAs.
Conclusions:
- MAOIs and SSRIs show promise in reducing AN use and mitigating early-stage oral fibrosis in preclinical models.
- The findings suggest a potential therapeutic role for MAOIs and SSRIs in managing AN addiction and its oral health consequences.
- Further research is warranted to optimize SSRI dosage or combination therapies, as potential 'boosting' may be necessary for sustained efficacy.
Related Concept Videos
02:59Cancer Prevention
Some...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:25Antidepressant Drugs: Overview
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists